Core Viewpoint - NanoViricides, Inc. is a clinical stage company focused on developing broad-spectrum antiviral drugs that are designed to be effective against viruses without the risk of escape [1] Group 1: Event Information - NanoViricides will present at the Pharma Partnering Summit 2025 on November 14, 2025, from 11:25 am to 11:45 am ET [1] - The event will take place at the Hilton Boston Logan Airport in Boston, MA [1]

Contact Us Back to the Newsroom The proposed Phase II clinical trial to evaluate safety and effectiveness of NV-387 for the treatment of patients with MPox disease caused by hMPXV infection is now cleared to proceed subject to filing of certain documents. "This is an important milestone in regulatory development of NV-387," said Anil R. Diwan, PhD, President and Executive Chairman of the Company. NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the ...

NV-387 Could be the Answer to the MPox Clade I Rising in the USA, Says Dr. Diwan SHELTON, CONNECTICUT / ACCESS Newswire / November 5, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that the Company will be holding its Annual Shareholders Meeting at 10 am on Saturday, November 8th, 2025, at the Hampton Inn & Suites Stamford, CT. Event Information: Event NanoViricides Annu ...